Blueprint Medicines(us:BPMC)

895000.00

+1.15%

Updated on 2025-04-30

Open:882100.00
Close:895000.00
High:899900.00
Low:870250.00
Prev Close:884800.00
Volume:1.11M
Turnover:98.56M
Turnover Ratio:1.71%
Shares:64.58M
MarketCap:57795.43B
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-3031766057649104.58%46111122
2024-03-3129965065282103.95%48100113
2023-12-3127163968832104.61%5966114
2023-09-3024064139055105.59%269581
2023-06-3024262702150103.40%2971106
2023-03-3124062552618103.54%288992
2022-12-3126562598926104.40%3188111
2022-09-3027162161915103.94%4069125
dateorgNametotalratiochangeShareschangeRatio
2024-06-30Blackrock Inc.664729710.52%1998363.10%
2024-06-30Vanguard Group Inc653846610.35%2284893.62%
2024-06-30Price T Rowe Associates Inc /Md/58733929.30%-377431-6.04%
2024-06-30Fmr Llc48336847.65%-335833-6.50%
2024-06-30Wellington Management Group Llp32355555.12%-939597-22.50%
2024-06-30Rock Springs Capital Management Lp24604173.90%-38031-1.52%
2024-06-30State Street Corp23798843.77%1871828.54%
2024-06-30William Blair Investment Management, Llc15939162.52%-114132-6.68%
2024-06-30Geode Capital Management, Llc14594842.31%883576.44%
2024-06-30Macquarie Group Ltd13120672.08%8290.06%

About

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Address:45 Sidney Street

Market Movers